Tuesday, December 16

Healthcare

Nuvectis gains on FDA’s orphan drug designation for cancer therapy

08/30/20241 Min Read

cancer designation drug FDAs gains Nuvectis orphan therapy

Previous ArticleNeurocrine upped to overweight by Piper, sees '568 as still viable

Next Article BioCardia shares climb as it gets FDA clearance for its Morph DNA product family